Cargando…

Chitosan-Based Nanoparticles for Targeted Nasal Galantamine Delivery as a Promising Tool in Alzheimer’s Disease Therapy

Natural alkaloid galantamine is widely used for the treatment of mild to moderate Alzheimer’s dementia. Galantamine hydrobromide (GH) is available as fast-release tablets, extended-release capsules, and oral solutions. However, its oral delivery can cause some unwanted side effects, such as gastroin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Georgieva, Dilyana, Nikolova, Denitsa, Vassileva, Elena, Kostova, Bistra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056147/ https://www.ncbi.nlm.nih.gov/pubmed/36986689 http://dx.doi.org/10.3390/pharmaceutics15030829

Ejemplares similares

Polyacrylamide/poly(2-(dimethylamino) Ethyl Methacrylate) Interpenetrating Polymer Networks as Drug Delivery Systems for Diclofenac Sodium
por: Grigorova, Kristina, et al.
Publicado: (2022)

Conceptualization and Investigation of Multicomponent Polymer Networks as Prospective Corticosteroid Carriers
por: Georgieva, Dilyana, et al.
Publicado: (2023)

L-Cysteine Modified Chitosan Nanoparticles and Carbon-Based Nanostructures for the Intranasal Delivery of Galantamine
por: Nanaki, Stavroula G., et al.
Publicado: (2022)

Interpenetrating Polymer Networks of Poly(2-hydroxyethyl methacrylate) and Poly(N, N-dimethylacrylamide) as Potential Systems for Dermal Delivery of Dexamethasone Phosphate
por: Simeonov, Marin, et al.
Publicado: (2023)

Hierarchical Porous Carbon—PLLA and PLGA Hybrid Nanoparticles for Intranasal Delivery of Galantamine for Alzheimer’s Disease Therapy
por: Nanaki, Stavroula G., et al.
Publicado: (2020)

Pharmacological investigations of new galantamine peptide esters
por: Tsvetkova, Dobrina, et al.
Publicado: (2014)

Poly(Sulfobetaine Methacrylate-co-Vinyl Pyrrolidone) Hydrogels as Potential Contact Lenses Delivery Systems for Timolol Maleate
por: Nikolova, Denitsa, et al.
Publicado: (2023)

Pharmacological aspects of galantamine for the treatment of Alzheimer's disease
por: Kim, Jae Kwang, et al.
Publicado: (2017)

Non-isothermal kinetics of thermal degradation of chitosan
por: Georgieva, Velyana, et al.
Publicado: (2012)

The Application of Mucoadhesive Chitosan Nanoparticles in Nasal Drug Delivery
por: Shim, Soojin, et al.
Publicado: (2020)

Chitosan-Coated Nanoparticles: Effect of Chitosan Molecular Weight on Nasal Transmucosal Delivery
por: Bruinsmann, Franciele Aline, et al.
Publicado: (2019)

Therapy of addition for Alzheimer's Disease: combination with galantamine and memantine
por: Zarra, Julio, et al.
Publicado: (2010)

Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
por: Seltzer, Ben
Publicado: (2010)

Galantamine plasma concentration and cognitive response in Alzheimer’s disease
por: Lin, Yi-Ting, et al.
Publicado: (2019)

Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application
por: Wattmo, Carina, et al.
Publicado: (2013)

Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease
por: Peters, Oliver, et al.
Publicado: (2015)

Ascorbic acid tethered polymeric nanoparticles enable efficient brain delivery of galantamine: An in vitro-in vivo study
por: Gajbhiye, Kavita R., et al.
Publicado: (2017)

The Prediction of Response to Galantamine Treatment in Patients with Mild to Moderate Alzheimer’s Disease
por: Ohnishi, Takashi, et al.
Publicado: (2014)

Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease
por: Siddique, Yasir Hasan, et al.
Publicado: (2022)

Mechanistic insights into MARK4 inhibition by galantamine toward therapeutic targeting of Alzheimer’s disease
por: Adnan, Mohd, et al.
Publicado: (2023)

In Vivo Characterization of ARN14140, a Memantine/Galantamine-Based Multi-Target Compound for Alzheimer’s Disease
por: Reggiani, Angelo M., et al.
Publicado: (2016)

Galantamine ameliorates experimental pancreatitis
por: Thompson, Dane A., et al.
Publicado: (2023)

Drug-Loaded Silver Nanoparticles—A Tool for Delivery of a Mebeverine Precursor in Inflammatory Bowel Diseases Treatment
por: Todorova, Mina, et al.
Publicado: (2023)

Hypothesis: apo‐lactoferrin–Galantamine Proteo‐alkaloid Conjugate for Alzheimer's disease Intervention
por: Akilo, Olufemi D., et al.
Publicado: (2018)

Chitosan nanoparticles as a promising tool in nanomedicine with particular emphasis on oncological treatment
por: Sharifi-Rad, Javad, et al.
Publicado: (2021)

Formulation and Evaluation of Galantamine Gel as Drug Reservoir in Transdermal Patch Delivery System
por: Fong Yen, Woo, et al.
Publicado: (2015)

Galantamine tethered hydrogel as a novel therapeutic target for streptozotocin-induced Alzheimer's disease in Wistar rats
por: Rajkumar, Manickam, et al.
Publicado: (2022)

Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease
por: Hager, Klaus, et al.
Publicado: (2014)

Efficacy of Galantamine on Cognition in Mild-to-Moderate Alzheimer's Dementia after Failure to Respond to Donepezil
por: Hwang, Tae-Young, et al.
Publicado: (2016)

Succinyl Chitosan-Colistin Conjugates as Promising Drug Delivery Systems
por: Dubashynskaya, Natallia V., et al.
Publicado: (2022)

Chitosan Aerogel Particles as Nasal Drug Delivery Systems
por: Menshutina, Natalia, et al.
Publicado: (2022)

Galantamine treatment in Alzheimer’s disease: response and long-term outcome in a routine clinical setting
por: Wallin, Åsa K, et al.
Publicado: (2011)

Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease [Corrigendum]
Publicado: (2014)

Formulation optimization of galantamine hydrobromide loaded gel drug reservoirs in transdermal patch for Alzheimer’s disease
por: Woo, Fong Yen, et al.
Publicado: (2015)

Galantamine as a Treatment Option for Nicotine Addiction
por: Jamali, Qutub
Publicado: (2021)

Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis
por: Hansen, Richard A, et al.
Publicado: (2008)

Galantamine Slows Down Plaque Formation and Behavioral Decline in the 5XFAD Mouse Model of Alzheimer’s Disease
por: Bhattacharya, Soumee, et al.
Publicado: (2014)

PT596. The comparison with galantamine and donepezil on Alzheimer’s Disease patients and its relationship with cerebral blood flow
por: Wake, Rei, et al.
Publicado: (2016)

Galantamine protects against beta amyloid peptide-induced DNA damage in a model for Alzheimer's disease
por: Castillo, Willian O., et al.
Publicado: (2017)

Acute response to cholinergic challenge predicts long‐term response to galantamine treatment in patients with Alzheimer's disease
por: Baakman, Anne Catrien, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nr5pf1mpeu3absiepil0tidcfv